TABLE 3.
Modern Pharmacological studies of A. sparsifolia.
Effect | Model | Part of plant/Extracts or compound | Positive control | Formulation/dosage | Result | References |
---|---|---|---|---|---|---|
Antioxidant | SOD, MDA, TEAC | Stem-branch/Curde polysaccharide | Lentinan (630 mg/kg) showed similar in vivo antioxidant activity to the extract | in vivo: 50, 100, 200 mg/kg | Increasing SOD TEAC leveals, decreasing MDA levels | Liu et al. (2021) |
Hepatoprotective effects | APAP-induced acute liver injury mice | Secretory/Aqueous | Silibinin (300 mg/kg) significantly inhibits ALT, AST activity and alleviates liver lesions caused by APAP | in vivo: 150, 300, 600 mg/kg | Inhibiting the release of ALT and AST caused by APAP overdose and alleviating APAP-induced liver injury and hepatocyte necrosis | Aili et al. (2017) |
Alcoholic-induced acute liver injury mice | Secretory/Aqueous | Silibinin has a protective effect in mice with alcoholic liver disease | in vivo: 150, 300, 600 mg/kg | promoting alcohol metabolism, reducing the expression levels of TNF-α and TLR4 mRNA, promoting liver tissue repair and hepatocyte regeneration | Kuerbanjiang et al. (2017) | |
Renoprotective effects | Gentamicin-induced subacute renal injury mice | Secretory/Aqueous | — | in vivo: 350 mg/kg | significant protective effect on renal injury caused by 125 and 80 mg/kg GM, but not on renal injury caused by 100 mg/kg GM | Mikeremu et al. (2013) |
HgCl2- induced subacute renal injury in mice | Secretory/Aqueous | — | in vivo: 150, 300, 750 mg/kg | Best renal protection at 150 mg/ml | Wumaierjiang et al. (2014) | |
Gastrointestinal effects | Atropine inhibition and bethanechol chloride promote small bowel motility | Secretory/Aqueous | — | in vivo: 750, 1,500, 3,000 mg/kg | Gastrointestinal motility is stimulated and inhibited by excited gastrointestinal motility | Mikeremu et al. (2017) |
Diarrheal irritable bowel syndrome rats | Aerial part/ethanol | TrimebutineMaleate (60 mg/kg) improves diarrhoeal irritable bowel syndrome | in vivo: 200, 400 mg/kg | The fecal moisture content, the AWR score and the level of 5- HT, SP, MTL in the high and low dose groups were significantly decreased, and the number of fecal grains increased significantly | Liu et al. (2019b) | |
Diarrheal irritable bowel syndrome rats | Aerial part/ethanol | TrimebutineMaleate (60 mg/kg) improves diarrhoeal irritable bowel syndrome | in vivo: 200, 400 mg/kg | At the concentration of 400 mg/kg, the extract significantly reduced wall electrical activity and increased NO levels | Ma et al. (2018c) | |
Affecting the survival rate | dry and hot environment rat | Aerial part/ethanol | — | in vivo: 100, 330, 1,000 mg/kg | Delaying the rise in core body temperature to improve heat tolerance in dry heat tolerance in rats in a dry heat environment | Dong et al. (2019) |
Immune regulation | RAW264.7 cells in mice | Secretory/Aqueous | Lipopolysaccharide (1,000 μg/ml) promote macrophage proliferation but are less active than extract (100, 200 μg/ml) | in vitro: 12.5, 25, 50, 100, 200 μg/ml | Promoting macrophage proliferation and having a positive regulatory effect on immune activity | Han et al. (2017) |
CY and DNCB induced delayed type hypersensitivity of immunosuppression mice | Aerial part/BuOH | — | in vivo: 100, 200, 400 mg/kg | Enhancing the swollen degree of auricle, resisting the atrophy of spleen and thymus and increasing the index of immune organs | Ma et al. (2017) | |
Anti-tumor | BGC-82, Eca-10, HT-29 and HepG2 cancer cells | Aerial part/ethanol | The IC50 values of Cisplatin for BGC-823, Eca-109, HT-29 and HepG2 cells were 0.019, 0.204, 0.0858, 0.0392 | in vitro: 10, 5, 2.5, 1.25, 0.625, 0.156, 0.039 mg/ml | The IC50 values of BGC-823, Eca-109, HT-29 and HepG2 cells were 1.62, 1.32, 1.55 and 1.45 mg/ml respectively | Ma et al. (2015) |
CT26 colon cancer mice | Inhibition rate of 98% in CT26 colon cancer mice by cyclophosphamide (50 mg/kg) | in vivo: 100, 200, 1,000 mg/kg | The inhibition rate was 24.8% in the high dose group, 0.06% in the medium dose group and -0.05% in the low dose group in vivo | |||
Hela, Ht-29, HepG2, BGC823 and KB tumour cells | Aerial part/EtOAc, BuOH, Compound 11, 65, 66, 98 and 167 | — | in vitro: 200, 100, 50, 25, 12.5, 6.25 μg/ml | inhibiting the proliferation and migration of Hela, Ht-29, HepG2, BGC823 and KB tumour cells in a dose-dependent manner | Ma et al. (2018b) | |
Anti-neuroinflammatory | LPS-induced N9 cells | Aerial part/ethanol | The IC50 values of minocycline for LPS-induced N9 cells was 19.89 | in vitro:/ | Compound 3, 4, 32, 37, 170, 171, 54, and 167 showed much stronger anti-neuroinflammatory effects than minocycline | Zhou et al. (2017) |